SAN DIEGO--(BUSINESS WIRE)--Today, DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announced they have begun enrolling patients in an Institutional Review Board approved, multicenter study for gene expression associated with basal cell carcinoma. Basal cell carcinoma will be the second product derived from DermTech’s Adhesive Skin Biopsy platform technology. DermTech’s Pigmented Lesion Assay helps clinicians non-invasively assess and differentiate unclear pigmented lesions including malignant melanomas from benign nevi (often referred to as moles). Positive feedback and demand from both dermatologists and patients highlighted the need to make DermTech’s technology available to patients with other types of skin cancer including basal cell carcinoma. Basal cell carcinoma is the most common type of skin cancer with approximately 30% of Caucasians developing basal cell carcinoma within their lifetime. Over 4.5 million surgical biopsies for basal cell carcinoma are performed in the U.S. annually leading to fewer than 3 million confirmed diagnoses.
Help employers find you! Check out all the jobs and post your resume.
